

Annual Report of Nation-Wide Survey of Cutaneous Lymphomas in Japan (2023)

Kazuyasu Fujii, Takatoshi Shimauchi, Tomomitsu Miyagaki, Jun Asai, Yasuhiro Fujisawa, Norito Kato

The Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society

Result 1. Number of newly diagnosed primary cutaneous lymphoma patients in 2023

	Total		Neoplasm category	Male No.	Female No.	M/F	Age		
	No.	%					Median	Average±sd	Range
Total	395		%	235	160	1.47	68.5	65.5 ± 17.0	98 - 16
Mature T- and NK-cell neoplasms	330	83.5	100	196	134	1.46	66	63.4 ± 16.6	98 - 16
Mycosis fungoides	203	51.4	61.5	113	90	1.26	64	62.8 ± 16.8	98 - 16
Sézary syndrome	9	2.3	2.7	8	1	8.00	71	67.7 ± 10.8	83 - 49
Primary cutaneous CD30+ T-cell lymphoproliferative disorders	31	7.8	9.4	20	11	1.82	68	61.3 ± 17.0	88 - 22
Primary cutaneous anaplastic large cell lymphoma	20	5.1	6.1	14	6	2.33	68.5	61.5 ± 18.4	88 - 22
Lymphomatoid papulosis	11	2.8	3.3	6	5	1.20	66	61.1 ± 14.2	78 - 37
Adult T-cell leukemia/lymphoma (smoldering type)	18	4.6	5.5	12	6	2.00	69	65.7 ± 14.0	92 - 36
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder	13	3.3	3.9	5	8	0.63	72	68.6 ± 13.5	88 - 38
Subcutaneous panniculitis-like T-cell lymphoma	13	3.3	3.9	8	5	1.60	58	53.9 ± 18.3	79 - 22
Primary cutaneous $\gamma\delta$ T-cell lymphoma	0	0.0	0.0	0	0	-	-	-	-
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder	0	0.0	0.0	0	0	-	-	-	-
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma	0	0.0	0.0	0	0	-	-	-	-
Primary cutaneous peripheral T-cell lymphoma, NOS	30	7.6	9.1	22	8	2.75	68	66.5 ± 14.3	94 - 35
Sever mosquito bite allergy	0	0.0	0.0	0	0	-	-	-	-
Hydroa vacciniforme lymphoproliferative disorder	0	0.0	0.0	0	0	-	-	-	-
Extranodal NK-/T-cell lymphoma	13	3.3	3.9	8	5	1.60	76	68.7 ± 19.5	92 - 32
Mature B-cell neoplasms	65	16.5	100	39	26	1.50	79	76.4 ± 12.2	96 - 30
Primary cutaneous marginal zone lymphoma	6	1.5	9.2	4	2	2.00	74.5	64.8 ± 18.4	80 - 30
Primary cutaneous follicle center lymphoma	20	5.1	30.8	15	5	3.00	72	71.5 ± 11.0	92 - 48
Primary cutaneous diffuse large B-cell lymphoma, leg type	33	8.4	50.8	17	16	1.06	82	81.5 ± 8.7	96 - 63
EBV+ mucocutaneous ulcer	0	0.0	0.0	0	0	-	-	-	-
other	6	1.5	9.2	3	3	1.00	76	76.5 ± 9.5	92 - 64

Result 2. All patients with primary cutaneous lymphoma registered in 2023

	Total		Neoplasm category	Male No.	Female No.	M/F	Age		
	No.	%					Median	Average±sd	Range
Total	2255		%	1218	1037	1.17	69	66.0 ± 16.0	98 - 5
Mature T- and NK-cell neoplasms	2057	91.2	100	1103	954	1.16	68	65.5 ± 16.0	98 - 5
Mycosis fungoides	1532	67.9	74.5	809	723	1.12	68	65.6 ± 15.6	98 - 15
Sézary syndrome	42	1.9	2.0	30	12	2.50	71	69.7 ± 14.2	91 - 33
Primary cutaneous CD30+ T-cell lymphoproliferative disorders	228	10.1	11.1	116	112	1.04	65	62.1 ± 17.3	95 - 5
Primary cutaneous anaplastic large cell lymphoma	137	6.1	6.7	74	63	1.17	66	64.3 ± 15.8	95 - 19
Lymphomatoid papulosis	91	4.0	4.4	42	49	0.86	59	58.7 ± 19.0	91 - 5
Adult T-cell leukemia/lymphoma (smoldering type)	85	3.8	4.1	46	39	1.18	73	70.9 ± 11.7	95 - 36
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder	35	1.6	1.7	19	16	1.19	67	65.9 ± 17.4	91 - 13
Subcutaneous panniculitis-like T-cell lymphoma	29	1.3	1.4	14	15	0.93	58	56.2 ± 17.9	83 - 22
Primary cutaneous $\gamma\delta$ T-cell lymphoma	2	0.1	0.1	0	2	0.00	75	-	82 - 68
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder	1	0.0	0.0	1	0	-	76	-	-
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma	0	0.0	0.0	0	0	-	-	-	-
Primary cutaneous peripheral T-cell lymphoma, NOS	83	3.7	4.0	54	29	1.86	69	66.5 ± 18.1	96 - 16
Sever mosquito bite allergy	1	0.0	0.0	0	1	0.00	71	-	-
Hydroa vacciniforme lymphoproliferative disorder	1	0.0	0.0	1	0	-	18	-	-
Extranodal NK-/T-cell lymphoma	18	0.8	0.9	13	5	2.60	75.5	70.7 ± 17.2	92 - 32
Mature B-cell neoplasms	198	8.8	100	115	83	1.39	74	71.9 ± 14.3	96 - 22
Primary cutaneous marginal zone lymphoma	77	3.4	38.9	45	32	1.41	68	65.6 ± 16.2	91 - 22
Primary cutaneous follicle center lymphoma	57	2.5	28.8	38	19	2.00	73	71.9 ± 11.8	93 - 36
Primary cutaneous diffuse large B-cell lymphoma, leg type	57	2.5	28.8	28	29	0.97	82	80.1 ± 9.0	96 - 58
EBV+ mucocutaneous ulcer	0	0.0	0.0	0	0	-	-	-	-
other	7	0.3	3.5	4	3	1.33	72	74.7 ± 9.8	92 - 64

Result 3. Number of secondary cutaneous lymphoma patients registered in 2023

	Newly-diagnosed		Male/Female		M/F	All registered		Male/Female		M/F
	No.	%	No.	No.		No.	%	No.	No.	
Total	256	100	142	114	1.25	437	100	236	201	1.17
Diffuse large B-cell lymphoma	85	33.2	52	33	1.58	107	24.5	67	40	1.68
Marginal zone lymphoma	8	3.1	3	5	0.60	11	2.5	5	6	0.83
Follicular lymphoma	8	3.1	4	4	1.00	14	3.2	8	6	1.33
Mantle cell lymphoma	3	1.2	2	1	2.00	6	1.4	3	3	1.00
Intravascular lymphoma	45	17.6	18	27	0.67	55	12.6	26	29	0.90
Adult T-cell leukemia/lymphoma (except smoldering type)	44	17.2	24	20	1.20	125	28.6	61	64	0.95
Nodal TFH cell lymphoma, angioimmunoblastic-type	4	1.6	3	1	3.00	13	3.0	5	8	0.63
Anaplastic large cell lymphoma, ALK-positive	2	0.8	1	1	1.00	5	1.1	2	3	0.67
Anaplastic large cell lymphoma, ALK-negative	5	2.0	4	1	4.00	16	3.7	13	3	4.33
Peripheral T-cell lymphoma, NOS (except primary cutaneous type)	8	3.1	5	3	1.67	11	2.5	7	4	1.75
Hodgkin lymphomas	4	1.6	2	2	1.00	6	1.4	4	2	2.00
Polymorphic lymphoproliferative disorders arising in immune deficiency/ dysregulation	12	4.7	3	9	0.33	20	4.6	5	15	0.33
Langerhans cell histiocytosis	3	1.2	1	2	0.50	11	2.5	2	9	0.22
Blastic plasmacytoid dendritic cell neoplasm	9	3.5	7	2	3.50	13	3.0	10	3	3.33
Other	16	6.3	13	3	4.33	24	5.5	18	6	3.00

The authors thank the dermatology staff at each medical institution who provided data for this registry.